Evidence map›Paper›PMID 36836848›Full record

ArticleLife (Basel, Switzerland)2023

Silybin Showed Higher Cytotoxic, Antiproliferative, and Anti-Inflammatory Activities in the CaCo Cancer Cell Line while Retaining Viability and Proliferation in Normal Intestinal IPEC-1 Cells.

Dominika Faixová, Marek Ratvaj, Ivana Cingeľová Maruščáková, Gabriela Hrčková, Viera Karaffová, Zita Faixová, Dagmar Mudroňová

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Silymarin and Inflammation: Food for Thoughts.Antioxidants (Basel, Switzerland) · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dominika FaixováDepartment of Pharmaceutical Technology, Pharmacognosy and Botany, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.
Marek RatvajDepartment of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.ORCID 0000-0003-4508-2081
Ivana Cingeľová MaruščákováDepartment of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.
Gabriela HrčkováInstitute of Parasitology, Slovak Academy of Sciences, 040 01 Košice, Slovakia.
Viera KaraffováDepartment of Morphological Disciplines, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.ORCID 0000-0002-8424-367X
Zita FaixováDepartment of Biology and Physiology, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.
Dagmar MudroňováDepartment of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, 041 81 Košice, Slovakia.ORCID 0000-0002-8007-6237
University of Veterinary Medicine in Košice · SKSlovak Academy of Sciences · SK

Funding

Ministry of Education, Science, Research and Sport of the Slovak Republic 1/0554/21Slovak Academy of Sciences bilateral mobility project SAV-AV ČR No. 18-24University of Veterinary Medicine and Pharmacy in Košice, Slovak Republic IGA UVLF 12/2020
6 · The paper itself

Abstract

The anticancer potential of silymarin is well known, including its anti-inflammatory as well as antiproliferative effect mediated by influencing the cell cycle, suppression of apoptosis, and inhibition of cell-survival kinases. However, less is known about silybin, the main component of the silymarin complex, where studies indicate its dual effect on the proliferation and immune response of various cell types in a dose-dependent manner. Moreover, there is a lack of studies comparing the effect of silybin on the same type of healthy and tumor cells, especially intestinal ones. Therefore, our study aimed to investigate the concentration-dependent effect of silybin on the normal intestinal porcine epithelial cell line-1 (IPEC-1) and the human epithelial colorectal adenocarcinoma cell line (CaCo-2). The metabolic viability, cell cycle, mitochondrial membrane potential, apoptosis, and the relative gene expression for pro- and anti-inflammatory cytokines were monitored in cells treated with silybin. Silybin stimulates metabolic viability as well as proliferation in IPEC-1 cells, protects the mitochondrial membrane, and thus exerts a cytoprotective effect, and has only a minimal effect on the gene expression of pro-inflammatory cytokines but significantly increases the expression of anti-inflammatory TGF-β. In contrast, it inhibits metabolic viability in tumor intestinal CaCo-2 cells, has an antiproliferative effect accompanied by increased apoptosis, and significantly reduces the expression of genes for pro-inflammatory interleukins as well as TGF-β. The antiproliferative and anti-inflammatory effect of silybin on tumor intestinal cells without a negative effect on healthy cells is a prerequisite for its potential use in the adjuvant therapy of colon cancer; however, further studies are necessary.

Indexed as

cell cyclecolon cancercytokineSilybum marianum

Identifiers

PMID36836848
PMCPMC9964225
OpenAlexW4319971936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.